博瑞医药：全资子公司增资扩股

Group 1 - The core point of the news is that Borui Pharmaceutical plans to introduce an investor, Suzhou Xinborui, through a capital increase in its wholly-owned subsidiary Borui Taixing, which will result in a change in ownership structure [1] - Suzhou Xinborui will subscribe to an additional registered capital of 22.68 million RMB, with the total investment amounting to 198 million RMB, while approximately 175 million RMB will be allocated to the capital reserve [1] - After the capital increase, Borui Taixing's registered capital will rise from 55 million RMB to 77.68 million RMB, and Borui Pharmaceutical's ownership in Borui Taixing will decrease from 100% to 70.8% [1] Group 2 - Borui Pharmaceutical's market capitalization is currently 24.5 billion RMB [2] - For the fiscal year 2024, the revenue composition of Borui Pharmaceutical is projected to be 97.33% from the pharmaceutical manufacturing sector and 2.67% from other businesses [1]